Wall Street Zen Upgrades Acrivon Therapeutics (NASDAQ:ACRV) to “Hold”

Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Sunday.

A number of other equities research analysts have also issued reports on the company. HC Wainwright reissued a “buy” rating and set a $19.00 price target on shares of Acrivon Therapeutics in a research note on Tuesday, November 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Acrivon Therapeutics in a research note on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Acrivon Therapeutics has an average rating of “Moderate Buy” and an average price target of $11.00.

Acrivon Therapeutics Trading Up 7.4%

ACRV stock opened at $2.32 on Friday. The stock has a market cap of $73.22 million, a PE ratio of -1.09 and a beta of 1.75. Acrivon Therapeutics has a 12 month low of $1.05 and a 12 month high of $8.00. The company has a 50-day moving average price of $2.21 and a 200 day moving average price of $1.70.

Acrivon Therapeutics (NASDAQ:ACRV) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.10. Sell-side analysts forecast that Acrivon Therapeutics will post -2.49 EPS for the current year.

Institutional Investors Weigh In On Acrivon Therapeutics

Hedge funds have recently made changes to their positions in the company. UBS Group AG increased its stake in shares of Acrivon Therapeutics by 150,057.8% during the third quarter. UBS Group AG now owns 683,218 shares of the company’s stock valued at $1,237,000 after buying an additional 682,763 shares during the period. Two Sigma Investments LP grew its holdings in Acrivon Therapeutics by 76.2% during the 3rd quarter. Two Sigma Investments LP now owns 319,205 shares of the company’s stock worth $578,000 after acquiring an additional 138,033 shares in the last quarter. Jane Street Group LLC purchased a new position in Acrivon Therapeutics during the 2nd quarter valued at about $371,000. XTX Topco Ltd bought a new stake in shares of Acrivon Therapeutics in the 2nd quarter valued at about $126,000. Finally, Algert Global LLC purchased a new stake in shares of Acrivon Therapeutics in the 3rd quarter worth approximately $81,000. 71.62% of the stock is currently owned by hedge funds and other institutional investors.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.